for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hisamitsu Pharmaceutical Co Inc

4530.T

Latest Trade

5,340.00JPY

Change

20.00(+0.38%)

Volume

100,900

Today's Range

5,280.00

 - 

5,350.00

52 Week Range

3,820.00

 - 

7,200.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,320.00
Open
5,290.00
Volume
100,900
3M AVG Volume
3.16
Today's High
5,350.00
Today's Low
5,280.00
52 Week High
7,200.00
52 Week Low
3,820.00
Shares Out (MIL)
72.36
Market Cap (MIL)
453,077.30
Forward P/E
22.74
Dividend (Yield %)
1.56

Next Event

Dividend For 4530.T - 41.5000 JPY

Latest Developments

More

U.S. FDA Approves SECUADO Transdermal System, The First-And-Only Transdermal Patch For The Treatment Of Adults With Schizophrenia

Hisamitsu Pharmaceutical Signs Agreement With Kyowa Hakko Kirin For Parkinson's Disease Treatment Hisamitsu Is Developing

Hisamitsu Pharmaceutical Expected To Post 15 PCt Drop In H1 Operating Profit To 11 BLn Yen - Nikkei

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hisamitsu Pharmaceutical Co Inc

HISAMITSU PHARMACEUTICAL CO., INC. is a Japan-based pharmaceutical company. The Medical and Related Product segment, along with its subsidiaries and associated companies, mainly manufactures and sells pharmaceuticals and related products in Japan, as well as the United States, Brazil, Vietnam, China and Indonesia. The others business is engaged in the urban cable television broadcasting business and Internet connection service business, the sale and rearing of experimental animals, the sale of experimental equipment and materials, the purchase, manufacture and sale of packing materials, the non-life insurance agency business and advertising agency business, among others.

Industry

Biotechnology & Drugs

Contact Info

30F, Marunouchi Bldg., 2-4-1, Marunouchi

+81.3.52931700

http://www.hisamitsu.co.jp

Executive Leadership

Hirotaka Nakatomi

Chairman of the Board, Representative Director

Kazuhide Nakatomi

President, Representative Director

Shinichiro Takao

Executive Officer, Chief Director of BU, Director of Finance, Manager of IR Office, President of Subsidiary, Director

Naruhito Higo

Chairman of Subsidiary, Director

Kosuke Sugiyama

Senior Managing Director, Executive Officer

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (JPY)

2017

241.270

2018

228.520

2019

230.080

2020(E)

233.900
Price To Earnings (TTM)
25.11
Price To Sales (TTM)
3.30
Price To Book (MRQ)
1.80
Price To Cash Flow (TTM)
19.78
Total Debt To Equity (MRQ)
0.69
LT Debt To Equity (MRQ)
0.17
Return on Investment (TTM)
6.73
Return on Equity (TTM)
5.90

Latest News

Latest News

BRIEF-Hisamitsu Pharmaceutical to set up pharmaceutical import and sales unit in Hong Kong

* Says it will set up a wholly owned pharmaceutical import and sales unit, Hisamitsu Pharmaceutical (Hong Kong) Co., Limited, in February

BRIEF-Hisamitsu Pharmaceutical's operating profit probably shrank 3 percent to 12.5 billion yen - Nikkei

* Hisamitsu pharmaceutical's operating profit probably shrank 3 percent to 12.5 billion yen ($111 million) in the March-August period - Nikkei

BRIEF-Hisamitsu Pharmaceutical to set up subsidiary in China

* Says it will set up a wholly owned subsidiary in China in August

BRIEF-Hisamitsu Pharmaceutical's sales for March-May qtr seen down 8 pct - Nikkei

* Hisamitsu Pharmaceutical's group operating profit appears to have declined 13% on the year to just under 5 billion yen for March-May quarter - Nikkei

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up